These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 12164886)

  • 1. Dual renin-angiotensin system blockade at optimal doses for proteinuria.
    Laverman GD; Navis G; Henning RH; de Jong PE; de Zeeuw D
    Kidney Int; 2002 Sep; 62(3):1020-5. PubMed ID: 12164886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Add-on angiotensin receptor blockade with maximized ACE inhibition.
    Agarwal R
    Kidney Int; 2001 Jun; 59(6):2282-9. PubMed ID: 11380832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
    Luño J; Barrio V; Goicoechea MA; González C; de Vinuesa SG; Gómez F; Bernis C; Espinosa M; Ahijado F; Gómez J; Escalada P
    Kidney Int Suppl; 2002 Dec; (82):S47-52. PubMed ID: 12410855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.
    Renke M; Tylicki L; Rutkowski P; Wojnarowski K; Lysiak-Szydlowska W; Rutkowski B
    Scand J Urol Nephrol; 2005; 39(6):511-7. PubMed ID: 16303729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Short-term observation.
    Tylicki L; Rutkowski P; Renke M; Rutkowski B
    Am J Nephrol; 2002; 22(4):356-62. PubMed ID: 12169868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency.
    Hou FF; Xie D; Zhang X; Chen PY; Zhang WR; Liang M; Guo ZJ; Jiang JP
    J Am Soc Nephrol; 2007 Jun; 18(6):1889-98. PubMed ID: 17494885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria.
    Laverman GD; Henning RH; de Jong PE; Navis G; de Zeeuw D
    Am J Kidney Dis; 2001 Dec; 38(6):1381-4. PubMed ID: 11728979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline].
    Renke M; Rutkowski P; Tylicki L; Zietkiewicz M; Larczyński W; Rutkowski B
    Przegl Lek; 2008; 65(6):312-4. PubMed ID: 18853664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis.
    Rutkowski P; Tylicki L; Renke M; Korejwo G; Zdrojewski Z; Rutkowski B
    Am J Kidney Dis; 2004 Feb; 43(2):260-8. PubMed ID: 14750091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individual titration for maximal blockade of the renin-angiotensin system in proteinuric patients: a feasible strategy?
    Vogt L; Navis G; de Zeeuw D
    J Am Soc Nephrol; 2005 Mar; 16 Suppl 1():S53-7. PubMed ID: 15938035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiproteinuric effect of losartan in non-diabetic renal disease is not dependent on ACE insertion/deletion polymorphism.
    Park HC; Choi HY; Kim BS; Kang SW; Choi KH; Ha SK; Lee HY; Han DS
    Kidney Blood Press Res; 2006; 29(4):216-24. PubMed ID: 16960460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute renal failure during lisinopril and losartan therapy for proteinuria.
    Hanevold CD
    Pharmacotherapy; 2006 Sep; 26(9):1348-51. PubMed ID: 16945058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial.
    Weiss RJ; Stapff M; Lin Y
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):129-40. PubMed ID: 23519546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.
    Mehdi UF; Adams-Huet B; Raskin P; Vega GL; Toto RD
    J Am Soc Nephrol; 2009 Dec; 20(12):2641-50. PubMed ID: 19926893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
    Andersen S; Tarnow L; Rossing P; Hansen BV; Parving HH
    Kidney Int; 2000 Feb; 57(2):601-6. PubMed ID: 10652037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of AT1 blocker fails to overcome resistance to ACE inhibition in adriamycin nephrosis.
    Bos H; Henning RH; De Boer E; Tiebosch AT; De Jong PE; De Zeeuw D; Navis G
    Kidney Int; 2002 Feb; 61(2):473-80. PubMed ID: 11849387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade.
    Humalda JK; Lambers Heerspink HJ; Kwakernaak AJ; Slagman MC; Waanders F; Vervloet MG; Ter Wee PM; Navis G; de Borst MH;
    Am J Kidney Dis; 2015 Feb; 65(2):259-66. PubMed ID: 25278093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.
    Russo D; Minutolo R; Pisani A; Esposito R; Signoriello G; Andreucci M; Balletta MM
    Am J Kidney Dis; 2001 Jul; 38(1):18-25. PubMed ID: 11431176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses.
    Segura J; Praga M; Campo C; Rodicio JL; Ruilope LM
    J Renin Angiotensin Aldosterone Syst; 2003 Mar; 4(1):43-7. PubMed ID: 12692753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor.
    Hasler C; Nussberger J; Maillard M; Forclaz A; Brunner HR; Burnier M
    Clin Pharmacol Ther; 2005 Nov; 78(5):501-7. PubMed ID: 16321616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.